Dr. Hammers on the CheckMate-214 Study for RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCCПодробнее

Dr. McKay Discusses the CheckMate-214 Trial in RCCПодробнее

Dr. Hammers on Combinations of IDO and PD-1 Inhibitors in RCCПодробнее

Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCCПодробнее

Dr. Pal on the CheckMate-214 and CABOSUN Studies in RCCПодробнее

Dr. Hammers on Nivolumab/Ipilimumab Data in RCCПодробнее

Dr. McDermott on an Analysis of the CheckMate-214 Study in RCCПодробнее

CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCCПодробнее

Dr. Hammers on Next Steps with Immunotherapy in RCCПодробнее

ASCO GU24 special: Prof. Nizar Tannir shares CheckMate 214 resultsПодробнее

Dr. Amin on Rationale for CheckMate-214 Trial in RCCПодробнее

Dr. Powles on the 42-Month Follow-Up Data From the CheckMate-214 Trial in RCCПодробнее

Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCCПодробнее

Michael Atkins, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in RCC patientsПодробнее

Dr. Hammers on Immunotherapy Combinations in Kidney CancerПодробнее

Dr. Hammers on the Future of Immunotherapy in RCCПодробнее

Phase 3 CheckMate - 214Подробнее

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCCПодробнее